Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.51 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.51 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.51 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.49 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.49 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.49 |
| ▸ | SMPD3 | Q9NY59 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | PIM3 | Q86V86 | 9/20 | 0.44 |
| ▸ | PIM2 | Q9P1W9 | 9/20 | 0.44 |
| ▸ | PIM1 | P11309 | 7/20 | 0.44 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.40 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.40 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6526399 | 1.00 | ROCK2 (0.51) | ROCK2ROCK1CDC42BPBSMARCA2SMARCA4 | |
| SCHEMBL11908053 | 0.84 | PIM2 (0.56) | ROCK2ROCK1CDC42BPBPIM3PIM2 | |
| SCHEMBL11906992 | 0.84 | PIM2 (0.56) | ROCK2ROCK1CDC42BPBPIM3PIM2 | |
| SCHEMBL4398719 | 0.82 | MAPT (0.45) | ROCK2ROCK1CDC42BPBMAPTPIM3 | |
| SCHEMBL19943253 | 0.82 | KDM4E (0.57) | MAPTPIM3PIM2PIM1 | |
| SCHEMBL15783900 | 0.81 | MAPT (0.52) | ROCK2ROCK1CDC42BPBSMARCA2SMARCA4 | |
| SCHEMBL28561328 | 0.81 | PBK (0.47) | MAPTPIM3PIM2PIM1PBK | |
| SCHEMBL21013405 | 0.79 | MAPT (0.45) | ROCK2ROCK1CDC42BPBMAPTPIM3 | |
| SCHEMBL15783997 | 0.79 | ROCK2 (0.54) | ROCK2ROCK1CDC42BPBMAPTPIM3 | |
| SCHEMBL11984697 | 0.79 | ROCK2 (0.48) | ROCK2ROCK1CDC42BPBSMARCA2SMARCA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2475659-B1 | 4-SUBSTITUTED PYRIDIN-3-YL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2015-10-28 | — | — | EP | disclosed |
| US-20140249135-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2014-09-04 | — | — | US | disclosed |
| US-8822497-B2 | PIM kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2014-09-02 | — | — | US | disclosed |
| EP-2132177-B1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2013-07-17 | — | — | EP | disclosed |
| US-8435976-B2 | 4-substituted pyridin-3-yl-carboxamide compounds and methods of use | F. HOFFMANN-LA ROCHE (CH) | 2013-05-07 | — | — | US | disclosed |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| EP-2475659-A1 | 4-SUBSTITUTED PYRIDIN-3-YL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2012-07-18 | — | — | EP | disclosed |
| WO-2011029802-A1 | 4-SUBSTITUTED PYRIDIN-3-YL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-17 | — | — | WO | disclosed |
| US-20110059961-A1 | 4-SUBSTITUTED PYRIDIN-3-YL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249135-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | ROCK2 519/4885ROCK1 453/4885CDC42BPB 297/4885 |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | ROCK2 519/4885ROCK1 453/4885CDC42BPB 297/4885 |
| US-20110059961-A1 | 4-SUBSTITUTED PYRIDIN-3-YL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | PIM1, PIM3, PIM2 | ROCK2 492/4885ROCK1 421/4885CDC42BPB 671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.